Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey | AVESİS

Istanbul Medipol University Research Information System

Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Copy For Citation

BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., TUĞLULAR A. T., ARSLAN Ö., GÖKER H., ...More

17th International Myeloma Workshop, Boston, United States Of America, 12 - 15 September 2019, vol.19, pp.242-243

Publication Type: Conference Paper / Full Text
Volume: 19
Doi Number: 10.1016/j.clml.2019.09.402
City: Boston
Country: United States Of America
Page Numbers: pp.242-243
Keywords: elotuzumab, immunomodulatory drugs, Multiple myeloma
Istanbul Medipol University Affiliated: No